High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
1.48M
-78.4%
--
--
1.83M
-66.12%
--
--
2.05M
-58.53%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for BioLineRx Ltd. (BLRX) for FY2025, with the revenue forecasts being adjusted by -48.88% over the past three months. During the same period, the stock price has changed by 4.57%.
Revenue Estimates for FY2025
Revise Downward
-48.88%
In Past 3 Month
Stock Price
Go Up
+4.57%
In Past 3 Month
2 Analyst Rating
0Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is 26.00 USD with a low forecast of 26.00 USD and a high forecast of 26.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
1 Hold
0 Sell
Moderate Buy
0Current: 3.660
Low
26.00
Averages
26.00
High
26.00
0Current: 3.660
Low
26.00
Averages
26.00
High
26.00
Jones Trading
Justin Walsh
Strong Buy
to
Hold
Downgrades
n/a
2025-04-02
Reason
Jones Trading
Justin Walsh
Price Target
n/a
2025-04-02
Downgrades
Strong Buy
to
Hold
Reason
JonesResearch analyst Justin Walsh downgraded BioLineRx to Hold from Buy without a price target following the Q4 report. BioLineRx is on "sounder financial footing" following cessation of U.S. commercial operations with a cash runway that extends into the second half of 2026, the analyst tells investors in a research note. However, the firm sees the stock remaining range bound until the company's pipeline assets are in-licensed or motixafortide generates additional favorable data in pancreatic cancer and gene therapy indications.
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$9 → $26
2025-03-31
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$9 → $26
2025-03-31
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Maintains
$21 → $9
2024-11-25
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21 → $9
2024-11-25
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$21
2024-11-06
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21
2024-11-06
Reiterates
Strong Buy
Reason
Jones Trading
Justin Walsh
Strong Buy
Initiates
$2
2024-09-04
Reason
Jones Trading
Justin Walsh
Price Target
$2
2024-09-04
Initiates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$21
2024-06-03
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$21
2024-06-03
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for BioLine RX Ltd (BLRX.O) is -0.97, compared to its 5-year average forward P/E of -1.35. For a more detailed relative valuation and DCF analysis to assess BioLine RX Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.35
Current PE
-0.97
Overvalued PE
0.19
Undervalued PE
-2.89
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-1.31
Current EV/EBITDA
-0.41
Overvalued EV/EBITDA
-0.10
Undervalued EV/EBITDA
-2.53
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
12.65
Current PS
2.05
Overvalued PS
56.22
Undervalued PS
-30.91
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
BLRX News & Events
Events Timeline
(ET)
2025-01-21
06:04:26
BioLineRx says current cash to provide runway through 2H26
2025-01-17 (ET)
2025-01-17
06:02:51
BioLineRx changes ratio of ADRs to ordinary shares
2025-01-06 (ET)
2025-01-06
07:59:44
BioLineRx announces $10M registered direct offering
Sign Up For More Events
Sign Up For More Events
News
Preview
9.5
05-20NewsfilterBioLineRx to Report First Quarter 2025 Results on May 27, 2025
Preview
9.5
04-03Yahoo FinanceBioLine Rx Ltd (BLRX) Q4 2024 Earnings Call Highlights: Strategic Licensing and Market ...
Preview
4.0
04-02BenzingaJones Trading Downgrades BioLine Rx to Hold
Sign Up For More News
People Also Watch
FAQ
What is BioLine RX Ltd (BLRX) stock price today?
What is BioLine RX Ltd (BLRX)'s business?
What is the price predicton of BLRX Stock?
What is BioLine RX Ltd (BLRX)'s revenue for the last quarter?
What is BioLine RX Ltd (BLRX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for BioLine RX Ltd (BLRX)'s fundamentals?
How many employees does BioLine RX Ltd (BLRX). have?